Evidence map›Paper›PMID 41333849›Full record

ArticleBMJ medicine2025

Trends in hypertension prevalence, control, and antihypertensive use in England from 2003 to 2021: insights from annual, nationwide Health Surveys for England.

Catherine Graham, James Steckelmacher, Jai Prashar, Ayesha Ahmed, Maxim Capel, Neil R Poulter, Peter Sedgwick Sever, Ajay Kumar Gupta

Abstract read
In one paragraph

Article in BMJ medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine Graham *William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London, UK.
James Steckelmacher *William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London, UK.ORCID https://orcid.org/0009-0009-8314-6630
Jai Prashar *William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London, UK.
Ayesha AhmedWilliam Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London, UK.
Maxim CapelLondon, UK.
Neil R PoulterImperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
Peter Sedgwick SeverNational Heart and Lung Institute, Imperial College London, London, UK.
Ajay Kumar GuptaWilliam Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0001-5807-8503

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To determine the annual trends over two decades in hypertension diagnosis, true hypertension prevalence, and control and use of antihypertensive drugs in England. Design: Annual, representative, nationwide Health Surveys for England from 2003 to 2021. Setting: Nationally representative sample consisting of participants from private households, identified through stratified, national, multistage sampling. Participants: 67 242 people older than 16 years surveyed between 2003 and 2021. Results: Between 2003 and 2021, the prevalence of measured hypertension decreased significantly from 37.8% in 2003 to 33.2% in 2018 (average annual percentage change (AAPC) -0.9%, 95% confidence interval -1.6% to -0.6%). Mean population systolic and diastolic blood pressure decreased significantly between 2003 to 2019 (systolic blood pressure from 128.7 to 124.0 mm Hg, AAPC -0.15%, -0.21% to -0.11%; diastolic blood pressure from 73.7 to 71.8 mm Hg, AAPC -0.12%, -0.20% to -0.04%). The prevalence of those with undiagnosed hypertension in the community decreased from 32.6% in 2003 to 23.7% in 2011, gradually worsening thereafter, with a steep increase in 2021 when 32.4% of those with hypertension were undiagnosed (AAPC -1.04%, -1.92% to -0.22%). Among people diagnosed (known) with hypertension, the proportion of those with blood pressure controlled to target increased across the study period (AAPC 1.66%, 0.04% to 2.27%), but this was mainly driven by the significant increase from 47.3% in 2003 to 56.5% in 2009 (AAPC 3.62%, 1.52% to 5.74%). A plateau was observed from 2011 onwards when there was no further significant improvement in the proportion of people with diagnosed (known) hypertension and blood pressure controlled to target. People with diagnosed (known) but uncontrolled hypertension showed a small but significant decrease in the mean number (standard deviation) of antihypertensive drugs used during the study period from 2.17 (0.86) in 2003 to 2.14 (0.96) in 2021 (AAPC -0.18%, -0.68% to -0.03%). Those with diagnosed (known) and controlled hypertension had no significant change in the mean number of drugs used. Conclusions: These findings indicate that there was a significant improvement in hypertension prevalence and control in the 2000s, with a plateau after 2011. The prevalence of undiagnosed hypertension in the community reduced in the early 2000s and 2010s, but has since returned to the same level as two decades ago.

Indexed as

EpidemiologyHealth policyHypertensionPrimary health carePublic health

Identifiers

PMID41333849
PMCPMC12666190

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.